Anika Therapeutics, Inc. Forecast, price target & analysts
Anika Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Anika Therapeutics, Inc. Classifications & Recommendation:
Anika Therapeutics, Inc. Price Target
| Target Price | $21.42 |
| Price | $10.74 |
| Potential |
99.44%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Anika Therapeutics, Inc. 2026 .
The average Anika Therapeutics, Inc. target price is $21.42.
This is
99.44%
register free of charge
$25.20
134.64%
register free of charge
$19.19
78.68%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Anika Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Anika Therapeutics, Inc. stock has an average upside potential 2026 of
99.44%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 119.91 | 112.16 |
| 0.73% | 6.46% | |
| EBITDA Margin | 4.85% | 0.01% |
| 67.65% | 99.79% | |
| Net Margin | -47.03% | -14.35% |
| 31.29% | 69.49% |
5 Analysts have issued a sales forecast Anika Therapeutics, Inc. 2025 . The average Anika Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Anika Therapeutics, Inc. EBITDA forecast 2025. The average Anika Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Anika Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Anika Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.83 | -1.12 |
| 32.09% | 70.76% | |
| P/E | negative | |
| EV/Sales | 0.90 |
5 Analysts have issued a Anika Therapeutics, Inc. forecast for earnings per share. The average Anika Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Anika Therapeutics, Inc....
Current Anika Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barrington Research |
Locked
➜
Locked
|
Locked | May 12 2025 |
| Barrington Research |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| Barrington Research |
Locked
➜
Locked
|
Locked | Nov 01 2024 |
| Barrington Research |
Locked
➜
Locked
|
Locked | Oct 22 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barrington Research:
Locked
➜
Locked
|
May 12 2025 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
Nov 01 2024 |
|
Locked
Barrington Research:
Locked
➜
Locked
|
Oct 22 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
